Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct;92(10):898-904.
doi: 10.1097/PHM.0b013e31829231fa.

Use of rimabotulinum toxin for focal hypertonicity management in children with cerebral palsy with nonresponse to onabotulinum toxin

Joline E Brandenburg  1 , Linda E Krach, Mark E Gormley Jr
Affiliations

Use of rimabotulinum toxin for focal hypertonicity management in children with cerebral palsy with nonresponse to onabotulinum toxin

Joline E Brandenburg et al. Am J Phys Med Rehabil. 2013 Oct.

Abstract

Objective: The aim of this study was to review the effect of rimabotulinum toxin (BoNT-B) for focal hypertonicity management in children with cerebral palsy and secondary nonresponse to onabotulinum toxin treated at the authors' tertiary care academic medical center.

Design: A retrospective review of the medical treatment of children was conducted at the authors' institution (March 16, 2001, to August 2, 2002) using the key words botulinum toxin B and Myobloc (Solstice Neurosciences Inc, South San Francisco, CA). Demographic information was analyzed using descriptive statistics (number [percentage] and mean [range]). The Pearson χ test was used to evaluate differences in incidence of adverse events.

Results: Eighty-two children had BoNT-B injections (116 treatments). Overall, 26.8% (19/71) of the children or their parents/guardians reported no or minimal response to the injections, with 89.5% (17/19) of these children having secondary nonresponse to onabotulinum toxin. Adverse events were frequent but did not require hospitalization of any patient. No significant differences were found in incidence of adverse events related to BoNT-B dosing, medical fragility, or Gross Motor Function Classification System level.

Conclusions: More than one-fourth of the children receiving BoNT-B injections had nonresponse, with most having previous nonresponse to onabotulinum toxin. Adverse events related to BoNT-B injections were frequent and unpredictable but not severe.

PubMed Disclaimer

References

    1. Carr LJ, Cosgrove AP, Gringras P, Neville BG for the UK Botulinum Toxin and Cerebral Palsy Working Party. Position paper on the use of botulinum toxin in cerebral palsy. Arch Dis Child. 1998;79:271–3. - PMC - PubMed
    1. Delgado MR, Hirtz D, Aisen M, et al. the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Practice parameter: Pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2010;74:336–43. - PMC - PubMed
    1. Schwerin A, Berweck S, Fietzek UM, et al. Botulinum toxin B treatment in children with spastic movement disorders: A pilot study. Pediatr Neurol. 2004;31:109–13. - PubMed
    1. Dressler D, Bigalke H. Botulinum toxin type B de novo therapy of cervical dystonia: Frequency of antibody induced therapy failure. J Neurol. 2005;252:904–7. - PubMed
    1. Dressler D, Bigalke H, Benecke R. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure. J Neurol. 2003;250:967–9. Corrected and republished in: J Neurol. 2003 Oct;250 (10):1263–5. - PubMed

Publication types

MeSH terms